Stigmast-5-en-3-ol induces apoptosis in cancer cells and inhibits cellular proliferation by increasing the production of Bax, Caspase-9, p53, and promoting PARP cleavage, while reducing Bcl-xl expression. It exhibits potent inhibitory activity against glucose amylase and α-amylase (α-amylase), and demonstrates high antioxidant activity. This compound is applicable in research related to leukemia, breast cancer, type 2 diabetes, and obesity.

Stigmast-5-en-3-ol (Compound DGEH21-3-2) exhibits cytotoxic effects on HL-60 and MCF-7 cells at concentrations of 12.5-50 μg/mL over a 24-hour period, with IC50 values of 37.82 and 45.17 μg/mL, respectively. It induces apoptosis in these cell lines, enhances DNA damage, and increases the levels of Bax, Caspase-9, p53, and PARP cleavage while reducing Bcl-xl. Additionally, Stigmast-5-en-3-ol (Compound 24R) at 2-10 μg/mL for 30 minutes strongly inhibits glucose amylase and α-amylase, with IC50 values of 5.8 and 7.198 µg/mL, and demonstrates significant radical activity.